ethyl [4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate | 325780-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: ethyl [4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate
• 英文别名: Ethyl (4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2h-benzo[f]isoindol-2-yl)phenyl)acetate；ethyl 2-[4-(4,9-diethoxy-1,3-dioxobenzo[f]isoindol-2-yl)phenyl]acetate
• CAS: 325780-78-7
• 化学式: C₂₆H₂₅NO₆
• 分子量: 447.488
• InChiKey: ZXHSGZRWRYZMTP-UHFFFAOYSA-N

物化性质

• 沸点：
  640.2±65.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl [4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(4-(4,9-Diethoxy-1,3-dioxo-1H-benzo[f]isoindol-2(3H)-yl)phenyl)acetic acid
  参考文献：
  名称：

  Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain

  摘要：

  A novel series of EP4 agonists and antagonists have been identified, and then used to validate their potential in the treatment of inflammatory pain. This paper describes these novel ligands and their activity within a number of pre-chmcal models of pain, ultimately leading to the identification of the EP4 partial agonist GSK726701A. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.03.091
• 作为产物：
  描述：

  邻苯二甲酸二乙酯 在 sodium ethanolate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 ethyl [4-(4,9-diethoxy-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate
  参考文献：
  名称：

  Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP4 receptor partial agonist for the treatment of pain

  摘要：

  A novel series of EP4 agonists and antagonists have been identified, and then used to validate their potential in the treatment of inflammatory pain. This paper describes these novel ligands and their activity within a number of pre-chmcal models of pain, ultimately leading to the identification of the EP4 partial agonist GSK726701A. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.03.091

文献信息

• Benzo'fisoindole derivatives with affinity to the ep4 receptor
  申请人：Congreve Stuart Miles

  公开号：US20050080257A1

  公开（公告）日：2005-04-14

  The present invention relates to a compound of formula (I): corresponding pharmaceutical compositions, preparation processes, and/or methods of using the aforementioned compounds and/or compositions.

  本发明涉及一种公式（I）的化合物，相应的药物组合物，制备方法，和/或使用上述化合物和/或组合物的方法。
• Benzo (f) insoindol derivatives and their use as ep4 receptor ligands
  申请人：——

  公开号：US20040087624A1

  公开（公告）日：2004-05-06

  Compounds of formula (I) 1 and pharmaceutically acceptable derivatives thereof bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

  式(I)1的化合物及其药学上可接受的衍生物具有高亲和力与EP4受体结合，可用于治疗或预防疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病等症状。
• Benzo[F]Isoindole Derivatives With Affinity To The EP4 Receptor
  申请人：Congreve Stuart Miles

  公开号：US20070088068A1

  公开（公告）日：2007-04-19

  A compound of formula (I) and processes for the preparation thereof.

  化合物式(I)及其制备方法。
• Benzo (F) insoindol derivatives and their use as EP4 receptor ligands
  申请人：Giblin Paul Gerard Martin

  公开号：US20060252799A1

  公开（公告）日：2006-11-09

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable derivatives thereof, which bind with high affinity to the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

  本发明涉及式（I）化合物及其药学上可接受的衍生物，它们具有高亲和力与EP4受体结合，可用于治疗或预防疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病等情况。
• NAPHTHALENE DERIVATIVES
  申请人：Congreve Miles Stuart

  公开号：US20080234358A1

  公开（公告）日：2008-09-25

  A compound of formula (I) wherein R 1 and R 3 are the same or different and represent ═O, hydrogen, C 1-6 alkyl, C 1-6 dialkyl, ═CHC 1 -C 5 alkyl, ═S, or a 5- or 6-membered aryl; R 4 to R 9 are the same or different and represent hydrogen, C 1-6 alkoxy, OCF 3 , OCH 2 CF 3 , O-cyclopropyl, OCH 2 -cyclopropyl, C 1 -C 6 alkyl, S-alkyl, NR 2 10 where R 10 is hydrogen or C 1-6 alkyl, halogen, NO 2 , OH, CH 2 OC 1 -C 6 alkyl, CH 2 OH, or CF 3 ; Q 1 is hydrogen, C 1-6 alkyl, C 1-6 dialkyl, C 1-6 alkoxy, NHAc, NR 2 10 where R 10 is hydrogen or C 1-6 alkyl, difluoro, fluoro, ═O, or OH; Q 2 , Q 3 , Q 4 and Q 5 are the same or different and represent hydrogen, C 1-6 alkoxy, OCF 3 , OCH 2 CF 3 , O-cyclopropyl, OCH 2 -cyclopropyl, C 1 -C 6 alkyl, S-alkyl, NR 2 10 where R 10 is hydrogen or C 1-6 alkyl, halogen, NO 2 , OH, CH 2 OC 1 -C 6 alkyl, CH 2 OH, or a 5- or 6-membered aryl; with the proviso that the compounds [4-(1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-2-propionic acid, sodium salt and [4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetic acid are excluded; and pharmaceutically acceptable derivatives thereof.

  式(I)的化合物，其中： R1和R3相同或不同，表示═O、氢、C1-6烷基、C1-6双烷基、═CHC1-C5烷基、═S或5-或6-成员芳基； R4到R9相同或不同，表示氢、C1-6烷氧基、OCF3、OCH2CF3、O-环丙基、OCH2-环丙基、C1-C6烷基、S-烷基、NR210（其中R10为氢或C1-6烷基）、卤素、NO2、OH、CH2OC1-C6烷基、CH2OH或CF3； Q1表示氢、C1-6烷基、C1-6双烷基、C1-6烷氧基、NHAc、NR210（其中R10为氢或C1-6烷基）、二氟、氟、═O或OH； Q2、Q3、Q4和Q5相同或不同，表示氢、C1-6烷氧基、OCF3、OCH2CF3、O-环丙基、OCH2-环丙基、C1-C6烷基、S-烷基、NR210（其中R10为氢或C1-6烷基）、卤素、NO2、OH、CH2OC1-C6烷基、CH2OH或5-或6-成员芳基； 但化合物[4-(1-氧代-1,3-二氢-2H-苯并[f]异吲哚-2-基)苯基]-2-丙酸，钠盐和[4-(4,9-二乙氧基-1-氧代-1,3-二氢-2H-苯并[f]异吲哚-2-基)苯基]乙酸除外；以及其药学上可接受的衍生物。